SAN DIEGO, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)IMMUNOTHERAPY FOUNDATION, founded in 2015, is a community nonprofit that reported $1.7M in total revenue in fiscal year 2020. Revenue surged 98% from the prior year, signaling strong growth momentum. Expenses of $1.5M left a modest 7% surplus.
Immunotherapy Foundations (IF) initial mission is to find an effective treatment, and ultimately a cure for HPV-related cancers through the partnering and funding of research, studies and revolutionary treatments broadly known as immunotherapy. This research falls under the following three broad immunotherapy categories: adoptive cell therapies, immune response vaccines, and novel drugs.All projects will be designed to bring promising human therapies to the clinic. The projects will address the biology of HPV-related cancers, particularly those of the head and neck. The current research shows promise to extend to other malignancies. The projects are tightly interconnected to leverage information, allowing efficient movement into the clinic.
Our cause is to fund the following programs and studies:A cutting-edge cancer mutanome focused personalized immunotherapy program.A novel immune therapy for head and neck squamous cell carcinoma...
Our cause is to fund the following programs and studies:A cutting-edge cancer mutanome focused personalized immunotherapy program.A novel immune therapy for head and neck squamous cell carcinoma (HNSCC) that lays the framework for developing drugs, antibodies, and vaccines against cancers.Identification of a novel immune biomarker in the RNA sequence that allows us to predict and assess a patients response to immunotherapy.A robust clinical trial portfolio of immunotherapies for patients with HPV-related cancers, stressing studies with novel therapies, translational research, and biomarker discovery.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2020 | 2019 | Change | |
|---|---|---|---|
| Revenue | $1,650,667 | $832,651 | +1.0% |
| Expenses | $1,533,551 | $1,265,054 | +0.2% |
| Net Income | $117,116 | $-432,403 | -1.3% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Christina B Jordan | Executive Dir. | 40.00 |
Officer
|
$160,000 | $0 | $160,000 |
| MARGAUX C STACK-BABICH | MANAGER | 40.00 |
|
$46,332 | $0 | $46,332 |
| FERNANDA L WHITWORTH | President | 20.00 |
Officer
Director
|
$0 | $0 | $0 |
| MARK MINASIAN | Treasurer | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| RANDY WOODS | Secretary | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2020 | $1,650,667 | $1,533,551 | $1,084,640 | $117,116 |
| 2019 | $832,651 | $1,265,054 | $446,267 | $-432,403 |
| 2018 | $483,908 | $817,470 | $877,650 | $-333,562 |
Compare IMMUNOTHERAPY FOUNDATION with other nonprofits in California and across the country.